Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan PM Asks Health Minister to Reform Pricing of Potential Blockbusters
September 28, 2023
- Ex-Senior Vice Minister Koga to Lead LDP’s Health Division
September 28, 2023
- Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
- Kamoshita Tapped as Advisor to PM on Drug, Dementia Policies
September 27, 2023
- Aichi Case of Death After COVID Shot Could Have Been Avoided with Adequate Steps: Report
September 27, 2023
- Japan to Balance Innovation, Finances in Leqembi Pricing: Minister
September 27, 2023
- Draft Revision of Basic Blood Product Policy OK’ed, to Be Finalized by March-End
September 27, 2023
- Leqembi Approval Marks New Era of Dementia Treatment: Japan PM
September 26, 2023
- Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
- Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
- Govt Must Bolster Leadership in Building Drug Discovery Ecosystem: New Minister
September 26, 2023
- Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
- Japan PM Announces Yen-Loan Program to Fight Pandemics
September 25, 2023
- Ex-Minister Tamura Tapped for No. 2 in LDP Policy Panel
September 25, 2023
- METI to Bankroll 95.5 Billion Yen in 23 Projects to Build Vaccine Sites, Moderna Among Them
September 22, 2023
- MHLW Panel Members Call for Tightening Advertising Regulations for Off-Label GLP-1 Use
September 22, 2023
- Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
- Chuikyo Rep Grumbles at Too Many Industry Requests, FPMAJ Chief Wants Health Coverage Dabate
September 21, 2023
- Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…